An oncogene regulating chromatin favors response to immunotherapy

References

• Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J. et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111. doi:10.1186/s13045-022-01325-0.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–14. doi:10.1016/S0140-6736(21)00797-2.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Yap D, Chan YH, Tan B, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar R. Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402. doi:10.1200/JCO.21.01862.
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J. et al. Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–1580. doi:10.1001/jamaoncol.2020.3370.
   PubMed Web of Science ®Google Scholar
• Hagi T, Kurokawa Y, Kawabata R, Omori T, Matsuyama J, Fujitani K, Hirao M, Akamaru Y, Takahashi T, Yamasaki M. et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. 2020;123(6):965–972. doi:10.1038/s41416-020-0975-7.
   PubMed Web of Science ®Google Scholar
• Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, Yatabe Y, Muro K. PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. J Gastrointest Oncol. 2021;12(6):2696–2705. doi:10.21037/jgo-21-505.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y. et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019;121(3):278–280. doi:10.1038/s41416-019-0515-5.
   PubMed Web of Science ®Google Scholar
• Dai X, Gao Y, Wei W. Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy. Semin Cancer Biol. 2022;85:246–252. doi:10.1016/j.semcancer.2021.04.002.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. doi:10.1186/s13045-019-0738-1.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672. doi:10.1016/j.annonc.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Sehgal P, Chaturvedi P. Chromatin and cancer: implications of disrupted chromatin organization in tumorigenesis and its diversification. Cancers Basel. 2023;15(2):466. doi:10.3390/cancers15020466.
   PubMed Web of Science ®Google Scholar
• Zhang FL, Li DQ. Targeting chromatin-remodeling factors in cancer cells: promising molecules in cancer therapy. Int J Mol Sci. 2022;23(21):12815. doi:10.3390/ijms232112815.
   PubMed Web of Science ®Google Scholar
• Mohammad A, Jha S. Epimutations and their effect on chromatin organization: exciting avenues for cancer treatment. Cancers Basel. 2022;15(1):215. doi:10.3390/cancers15010215.
   PubMed Web of Science ®Google Scholar
• Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P. et al. A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing. Sci. 2018;359(6377):770–775. doi:10.1126/science.aao1710.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang J, Zhou D, Wu Z, Liu W, Chen Y, Chen G, Zhang J. SWI/SNF complex genomic alterations as a predictive biomarker for response to immune checkpoint inhibitors in multiple cancers. Cancer Immunol Res. 2023;11(5):646–656. doi:10.1158/2326-6066.CIR-22-0813.
   PubMed Web of Science ®Google Scholar
• Zheng L, Liang X, Li S, Li T, Shang W, Ma L, Jia X, Shao W, Sun P, Chen C. et al. CHAF1A interacts with TCF4 to promote gastric carcinogenesis via upregulation of c-MYC and CCND1 expression. EBioMedicine. 2018;38:69–78. doi:10.1016/j.ebiom.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang N, Li X, Chen X, Shen B, Zhu D, Zhu L, Xu Y, Yu Y, Shu Y. et al. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer. 2021;24(4):823–834. doi:10.1007/s10120-021-01175-8.
   PubMed Web of Science ®Google Scholar
• Duan R, Li X, Zeng D, Chen X, Shen B, Zhu D, Zhu L, Yu Y, Wang D. Tumor microenvironment status predicts the efficacy of postoperative chemotherapy or radiochemotherapy in resected gastric cancer. Front Immunol. 2021;11:609337. doi:10.3389/fimmu.2020.609337.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen X, Du Y, Li X, Ying L, Lu Y, Shen B, Gao X, Yi X, Xia X. et al. Associations of HER2 mutation with immune-related features and immunotherapy outcomes in solid tumors. Front Immunol. 2022;13:799988. doi:10.3389/fimmu.2022.799988.
   PubMed Web of Science ®Google Scholar
• Lu Y, Li D, Cao Y, Ying L, Tao Q, Xiong F, Hu Z, Yang Y, Qiao X, Peng C. et al. A genomic signature reflecting fibroblast infiltration into gastric cancer is associated with prognosis and treatment outcomes of immune checkpoint inhibitors. Front Cell Dev Biol. 2022;10:862294. doi:10.3389/fcell.2022.862294.
   PubMed Web of Science ®Google Scholar
• Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458. doi:10.1038/s41591-018-0101-z.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H, Astarita JL, Cubas R. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA. et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Wang D, Li X, Shen B, Chen X, Shu Y. Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase. Gene. 2019;716:144034. doi:10.1016/j.gene.2019.144034.
   PubMed Web of Science ®Google Scholar
• Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu SJ, Ke A, Cui Y, Wang Z, Wang W. et al. Up-regulation of Krüppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology. 2010;139(6):2146–2157.e12. doi:10.1053/j.gastro.2010.08.004.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang W, Wang N, Ouyang D, Xiao L, Zhang S, Ou X, He T, Yu R, Song L. et al. Development of arteannuin B sustained-release microspheres for anti-tumor therapy by integrated experimental and molecular modeling approaches. Pharmaceutics. 2021;13(8):1236. doi:10.3390/pharmaceutics13081236.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cui F, Yu F, Peng X, Jiang T, Chen D, Lu S, Tang H, Peng Z. Up-regulation of CHAF1A, a poor prognostic factor, facilitates cell proliferation of colon cancer. Biochem Biophys Res Commun. 2014;449(2):208–215. doi:10.1016/j.bbrc.2014.05.006.
   PubMed Web of Science ®Google Scholar
• Tao L, Moreno-Smith M, Ibarra-García-Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B. et al. CHAF1A blocks neuronal differentiation and promotes neuroblastoma oncogenesis via metabolic reprogramming. Adv Sci (Weinh). 2021;8(19):e2005047. doi:10.1002/advs.202005047.
   PubMedGoogle Scholar
• Tauriello D, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543. doi:10.1038/nature25492.
   PubMed Web of Science ®Google Scholar
• Lin Y, Jing X, Chen Z, Pan X, Xu D, Yu X, Zhong F, Zhao L, Yang C, Wang B. et al. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. Theranostics. 2023;13(13):4574–4600. doi:10.7150/thno.86928.
   PubMed Web of Science ®Google Scholar
• Shen C, Li M, Duan Y, Jiang X, Hou X, Xue F, Zhang Y, Luo Y. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Front Immunol. 2023;14:1170207. doi:10.3389/fimmu.2023.1170207.
   PubMedGoogle Scholar
• Hoek M, Stillman B. Chromatin assembly factor 1 is essential and couples chromatin assembly to DNA replication in vivo. Proc Natl Acad Sci U S A. 2003;100(21):12183–12188. doi:10.1073/pnas.1635158100.
   PubMed Web of Science ®Google Scholar
• Sauer PV, Gu Y, Liu WH, Mattiroli F, Panne D, Luger K, Churchill ME. Mechanistic insights into histone deposition and nucleosome assembly by the chromatin assembly factor-1. Nucleic Acids Res. 2018;46(19):9907–9917. doi:10.1093/nar/gky823.
   PubMed Web of Science ®Google Scholar
• Sykaras AG, Pergaris A, Theocharis S. Challenging, accurate and feasible: CAF-1 as a tumour proliferation marker of diagnostic and prognostic value. Cancers Basel. 2021;13(11):2575. doi:10.3390/cancers13112575.
   PubMed Web of Science ®Google Scholar
• Ayoub J, Buonanno M, Di Fiore A, De Simone G, Monti SM. Biochemical and structural insights into the Winged Helix Domain of P150, the largest subunit of the Chromatin Assembly Factor 1. Int J Mol Sci. 2022;23(4):2160. doi:10.3390/ijms23042160.
   PubMed Web of Science ®Google Scholar
• Sun X, Ma Q, Cheng Y, Huang H, Qin J, Zhang M, Qu S. Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance. Front Genet. 2023;14:1108004. doi:10.3389/fgene.2023.1108004.
   PubMed Web of Science ®Google Scholar
• Sun R, Xie HY, Qian JX, Huang YN, Yang F, Zhang FL, Shao Z-M, Li D-Q. FBXO22 possesses both protumorigenic and antimetastatic roles in breast cancer progression. Cancer Res. 2018;78(18):5274–5286. doi:10.1158/0008-5472.CAN-17-3647.
   PubMed Web of Science ®Google Scholar
• Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS. et al. Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. Cancer Res. 2017;77(13):3417–3430. doi:10.1158/0008-5472.CAN-16-1616.
   PubMed Web of Science ®Google Scholar
• Yuan F, Sun Q, Zhang S, Ye L, Xu Y, Deng G, Xu Z, Zhang S, Liu B, Chen Q. et al. The dual role of p62 in ferroptosis of glioblastoma according to p53 status. Cell & Bioscience. 2022;12(1):20. doi:10.1186/s13578-022-00764-z.
   PubMed Web of Science ®Google Scholar
• Rozenberg JM, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D, Bessmertnyi A, Romanishin A, Alsoulaiman L, Kumeiko V. et al. Dual role of p73 in cancer microenvironment and DNA damage response. Cells. 2021;10(12):3516. doi:10.3390/cells10123516.
   PubMed Web of Science ®Google Scholar
• Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983–2994. doi:10.1016/j.apsb.2021.01.003.
   PubMed Web of Science ®Google Scholar
• Saxena S, Zou L. Hallmarks of DNA replication stress. Mol Cell. 2022;82(12):2298–2314. doi:10.1016/j.molcel.2022.05.004.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Zeng X, Zhou J, Xiong Z, Sun H, Yang W, Mok MTS, Wang J, Li J, Liu M, Tang W. et al. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cell Mol Immunol. 2021;18(4):1005–1015. doi:10.1038/s41423-020-00534-2.
   PubMed Web of Science ®Google Scholar